Learn About Pigment-Dispersion Syndrome

What is the definition of Pigment-Dispersion Syndrome?
Pigment-dispersion syndrome is an eye disorder that occurs when pigment granules that normally adhere to the back of the iris (the colored part of the eye) flake off into the clear fluid produced by the eye (aqueous humor). These pigment granules may flow towards the drainage canals of the eye, slowly clogging them and raising the pressure within the eye (intraocular pressure or IOP). This rise in eye pressure can cause damage to the optic nerve (the nerve in the back of the eye that carries visual images to the brain). If the optic nerve becomes damaged, Pigment-dispersion syndrome becomes pigmentary glaucoma. This happens in about 30% of cases. While men and women are affected in equal numbers, men develop pigmentary glaucoma up to 3 times more often than women. Myopia (nearsightedness) appears to be an important risk factor in the development of Pigment-dispersion syndrome and is present in up to 80% of affected individuals. The condition may be sporadic or follow an autosomal dominant pattern of inheritance with reduced penetrance . At least one gene locus on chromosome 7 has been identified.
Save information for later
Sign Up
What are the alternative names for Pigment-Dispersion Syndrome?
  • Pigment-dispersion syndrome
Who are the top Pigment-Dispersion Syndrome Local Doctors?
JS
Dr. Joel S. Schuman
Ophthalmology
Elite
Highly rated in
7
conditions
Ophthalmology

NYU Langone Health

NYU Langone Eye Center

222 E 41st St, 
New York, NY 

Joel Schuman is an Ophthalmologist in New York, New York. Schuman has been practicing medicine for over 39 years and is rated as an Elite expert by MediFind in the treatment of Pigment-Dispersion Syndrome. He is also highly rated in 7 other conditions, according to our data. His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Optic Glioma, and Cataract Removal. Schuman is currently accepting new patients.

LP
Dr. Louis R. Pasquale
Ophthalmology
Elite
Highly rated in
8
conditions
Ophthalmology

Mount Sinai Health System

Mount Sinai Medical Center

17 E 102nd St, 
New York, NY 

Louis Pasquale is an Ophthalmologist in New York, New York. Pasquale has been practicing medicine for over 37 years and is rated as an Elite expert by MediFind in the treatment of Pigment-Dispersion Syndrome. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Hormone Replacement Therapy (HRT), and Cataract Removal. Pasquale is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn more
RW
Dr. Robert N. Weinreb
Ophthalmology
Elite
Highly rated in
9
conditions
Ophthalmology

University of California San Diego Health System

Shiley Eye Institute

9415 Campus Point Dr, 
La Jolla, CA 

Robert Weinreb is an Ophthalmologist in La Jolla, California. Weinreb has been practicing medicine for over 48 years and is rated as an Elite expert by MediFind in the treatment of Pigment-Dispersion Syndrome. He is also highly rated in 9 other conditions, according to our data. His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Cataract Removal, and Corneal Transplant. Weinreb is currently accepting new patients.

View All Doctors
What are the latest Pigment-Dispersion Syndrome Clinical Trials?
ARGOS - A Phase IV, Prospective, 18-month Study to Assess the Effectiveness and Safety of Bimatoprost Intracameral Implant (DURYSTA) in US Clinical Practice
Enrollment Status: Recruiting
Publish Date: December 15, 2022

Summary: Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Ab Externo Implantation of Glaucoma Gel Stent
Enrollment Status: Recruiting
Publish Date: December 15, 2022
Intervention Type: Device
Study Phase: Phase 3

Summary: Glaucoma is the second most common cause of blindness in the world, second only to cataracts. This study will assess how safe and effective a glaucoma gel stent is when implanted using the ab externo approach. Adverse events and intraocular pressure will be assessed. XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted ...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Pigment-Dispersion Syndrome?
Efficacy and safety of a fixed combination drug Brinzolol Duo in the treatment of patients with primary open-angle glaucoma.
Condition: Primary Open-Angle Glaucoma (POAG)
Journal: Vestnik oftalmologii
Treatment Used: Brizolol and Timolol
Number of Patients: 120
Published: December 27, 2022
TUBE VERSUS TRABECULECTOMY IN JUVENILE-ONSET OPEN ANGLE GLAUCOMA - TREATMENT OUTCOMES IN TERTIARY HOSPITALS IN MALAYSIA.
Condition: Juvenile-Onset Open Angle Glaucoma (JOAG)
Journal: Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti
Treatment Used: Trabeculectomy
Published: December 21, 2022
Tired of the same old research?
Check Latest Advances
Roles of Toric intraocular Lens implantation on visual acuity and astigmatism in glaucomatous eyes treated with iStent and cataract surgery.
Condition: Glaucoma/Corneal Astigmatism/Cataract
Journal: BMC ophthalmology
Treatment Used: Toric Intraocular Lenses (IOLs) vs. Non-Toric Intraocular Lenses
Number of Patients: 18
Published: December 14, 2022
View All Latest Advances